VBI Common Stock vs Capital Stock Analysis
VBIV Stock | USD 0.57 0.01 1.79% |
VBI Vaccines financial indicator trend analysis is much more than just breaking down VBI Vaccines prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether VBI Vaccines is a good investment. Please check the relationship between VBI Vaccines Common Stock and its Capital Stock accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VBI Vaccines. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.
Common Stock vs Capital Stock
Common Stock vs Capital Stock Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of VBI Vaccines Common Stock account and Capital Stock. At this time, the significance of the direction appears to have very strong relationship.
The correlation between VBI Vaccines' Common Stock and Capital Stock is 0.82. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Capital Stock in the same time period over historical financial statements of VBI Vaccines, assuming nothing else is changed. The correlation between historical values of VBI Vaccines' Common Stock and Capital Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of VBI Vaccines are associated (or correlated) with its Capital Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Stock has no effect on the direction of Common Stock i.e., VBI Vaccines' Common Stock and Capital Stock go up and down completely randomly.
Correlation Coefficient | 0.82 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Common Stock
Capital Stock
The total amount of a company’s capital funded by shareholders through the issue and subscription of shares.Most indicators from VBI Vaccines' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into VBI Vaccines current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VBI Vaccines. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.At this time, VBI Vaccines' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to climb to about 35.9 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (0.76) in 2024.
2023 | 2024 (projected) | Non Recurring | 5.7M | 5.0M | Reconciled Depreciation | 2.0M | 1.6M |
VBI Vaccines fundamental ratios Correlations
Click cells to compare fundamentals
VBI Vaccines Account Relationship Matchups
High Positive Relationship
High Negative Relationship
VBI Vaccines fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 122.2M | 209.4M | 210.3M | 155.1M | 87.0M | 73.5M | |
Total Stockholder Equity | 88.3M | 171.7M | 143.9M | 64.2M | 7.5M | 7.2M | |
Property Plant And Equipment Net | 10.2M | 10.7M | 11.0M | 12.3M | 11.9M | 21.9M | |
Net Debt | (29.4M) | (92.9M) | (89.9M) | (10.4M) | 29.4M | 30.8M | |
Retained Earnings | (262.4M) | (308.6M) | (378.4M) | (489.6M) | (582.4M) | (553.3M) | |
Cash | 44.2M | 93.8M | 121.7M | 62.6M | 23.7M | 28.9M | |
Non Current Assets Total | 75.2M | 77.3M | 80.0M | 77.4M | 50.7M | 42.9M | |
Non Currrent Assets Other | 2.1M | 2.2M | 4.6M | 4.7M | 1.2M | 992.6K | |
Cash And Short Term Investments | 44.2M | 119.1M | 121.7M | 62.6M | 23.7M | 31.5M | |
Common Stock Shares Outstanding | 4.0M | 7.3M | 8.5M | 8.6M | 15.6M | 16.4M | |
Liabilities And Stockholders Equity | 122.2M | 209.4M | 210.3M | 155.1M | 87.0M | 73.5M | |
Other Current Assets | 450K | 1.3M | 2.2M | 8.4M | 2.8M | 2.9M | |
Other Stockholder Equity | 66.4M | 75.5M | 81.6M | 90.0M | 107.4M | 112.8M | |
Total Liab | 33.9M | 37.7M | 66.4M | 90.9M | 79.4M | 83.4M | |
Property Plant And Equipment Gross | 11.7M | 12.3M | 19.3M | 23.6M | 22.3M | 27.7M | |
Total Current Assets | 47.0M | 132.0M | 130.3M | 77.7M | 36.2M | 33.0M | |
Total Current Liabilities | 29.8M | 17.3M | 32.6M | 36.9M | 75.7M | 79.5M | |
Accounts Payable | 1.1M | 3.7M | 4.3M | 13.0M | 6.4M | 6.8M | |
Net Receivables | 201K | 77K | 8K | 94K | 1.3M | 1.3M | |
Non Current Liabilities Total | 4.2M | 20.3M | 33.8M | 54.0M | 3.7M | 3.5M | |
Accumulated Other Comprehensive Income | (752K) | 1.3M | (1.6M) | 21.4M | 28.3M | 29.7M | |
Other Assets | 620K | 2.2M | 1.3M | 1.4M | 1.0 | 0.95 | |
Short Long Term Debt Total | 14.8M | 944K | 31.8M | 52.2M | 53.0M | 55.7M | |
Inventory | 1.1M | 2.2M | 2.6M | 6.6M | 8.5M | 8.9M | |
Other Current Liab | 12.9M | 12.4M | 26.9M | 22.6M | 6.7M | 5.7M | |
Short Term Debt | 14.8M | 944K | 839K | 972K | 51.7M | 54.3M | |
Common Stock Total Equity | 285.0M | 403.5M | 442.2M | 442.3M | 508.7M | 260.5M | |
Common Stock | 285.0M | 403.5M | 442.2M | 442.3M | 454.2M | 247.1M | |
Net Tangible Assets | 25.3M | 107.3M | 79.5M | 3.7M | 4.2M | 4.0M | |
Current Deferred Revenue | 882K | 255K | 526K | 409K | 10.9M | 11.4M | |
Intangible Assets | 60.8M | 62.2M | 62.1M | 58.3M | 36.5M | 47.5M | |
Property Plant Equipment | 11.7M | 10.7M | 11.0M | 12.3M | 14.1M | 14.8M | |
Other Liab | 3.4M | 3.4M | 2.9M | 2.7M | 3.1M | 2.7M | |
Short Long Term Debt | 1.6M | 1.1M | 14.8M | 50.8M | 58.4M | 61.3M | |
Capital Surpluse | 66.4M | 75.5M | 81.6M | 90.0M | 103.5M | 75.2M | |
Good Will | 8.3M | 2.2M | 2.3M | 2.1M | 1.1M | 1.1M | |
Retained Earnings Total Equity | (262.4M) | (308.6M) | (378.4M) | (489.6M) | (440.6M) | (418.6M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards VBI Vaccines in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, VBI Vaccines' short interest history, or implied volatility extrapolated from VBI Vaccines options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.MSFT | Microsoft | |
CRM | Salesforce | |
GOOG | Alphabet Inc Class C |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VBI Vaccines. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for VBI Stock analysis
When running VBI Vaccines' price analysis, check to measure VBI Vaccines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VBI Vaccines is operating at the current time. Most of VBI Vaccines' value examination focuses on studying past and present price action to predict the probability of VBI Vaccines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VBI Vaccines' price. Additionally, you may evaluate how the addition of VBI Vaccines to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is VBI Vaccines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VBI Vaccines. If investors know VBI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VBI Vaccines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.03) | Revenue Per Share 0.558 | Quarterly Revenue Growth 1.911 | Return On Assets (0.29) | Return On Equity (2.59) |
The market value of VBI Vaccines is measured differently than its book value, which is the value of VBI that is recorded on the company's balance sheet. Investors also form their own opinion of VBI Vaccines' value that differs from its market value or its book value, called intrinsic value, which is VBI Vaccines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VBI Vaccines' market value can be influenced by many factors that don't directly affect VBI Vaccines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VBI Vaccines' value and its price as these two are different measures arrived at by different means. Investors typically determine if VBI Vaccines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VBI Vaccines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.